Capricor Therapeutics (CAPR)
NASDAQ:CAPR

Capricor Therapeutics (CAPR) Stock Price & Analysis

574 Followers

CAPR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.81 - $6.58
Previous Close$4.2
Volume89.79K
Average Volume (3M)122.28K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$46.61M
Total Debt (Recent Filing)$2.78M
Price to Earnings (P/E)-3.7
Beta-0.22
Next EarningsMar 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.13
Shares Outstanding25,241,402
R-Squared0.11
Standard Deviation0.68
10 Day Avg. Volume163,398
30 Day Avg. Volume122,285
Price to Book (P/B)6.90
Price to Sales (P/S)67.09
Price to Cash Flow (P/CF)16.60
P/FCF Ratio11.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Alpha0.03
Number of Analyst Covering2


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CAPR FAQ

What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $2.81 and its highest was $6.58 in the past 12 months.
    What is Capricor Therapeutics’s market cap?
    Currently, no data Available
    When is Capricor Therapeutics’s upcoming earnings report date?
    Capricor Therapeutics’s upcoming earnings report date is Mar 15, 2023 which is in 40 days.
      How were Capricor Therapeutics’s earnings last quarter?
      Capricor Therapeutics released its earnings results on Nov 10, 2022. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.06.
        Is Capricor Therapeutics overvalued?
        According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Capricor Therapeutics pay dividends?
          Capricor Therapeutics does not currently pay dividends.
          What is Capricor Therapeutics’s EPS estimate?
          Capricor Therapeutics’s EPS estimate is -$0.34.
            How many shares outstanding does Capricor Therapeutics have?
            Capricor Therapeutics has 25,241,402 shares outstanding.
              What happened to Capricor Therapeutics’s price movement after its last earnings report?
              Capricor Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went down -7.143%.
                Which hedge fund is a major shareholder of Capricor Therapeutics?
                Among the largest hedge funds holding Capricor Therapeutics’s share is Oracle Investment Management Inc. It holds Capricor Therapeutics’s shares valued at N/A.

                  ---

                  Capricor Therapeutics Stock Smart Score

                  5
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  The Capricor Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Capricor Therapeutics

                  Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  GlycoMimetics
                  Nuvectis Pharma
                  Annovis Bio
                  ImmunoCellular Therapeutics

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis